Rocket Pharmaceuticals Stock Filter Stocks by Fundamentals
| RCKT Stock | USD 14.39 0.19 1.34% |
Rocket Pharmaceuticals fundamentals help investors to digest information that contributes to Rocket Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Rocket Stock. The fundamental analysis module provides a way to measure Rocket Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Rocket Pharmaceuticals stock.
Rocket | Shares Owned by Institutions |
Rocket Pharmaceuticals Current Valuation Drivers
We derive many important indicators used in calculating different scores of Rocket Pharmaceuticals from analyzing Rocket Pharmaceuticals' financial statements. These drivers represent accounts that assess Rocket Pharmaceuticals' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Rocket Pharmaceuticals' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 1.1B | 3.0B | 1.4B | 1.3B | 2.5B | 2.6B | |
| Enterprise Value | 977.5M | 2.8B | 1.2B | 1.2B | 2.5B | 2.6B |
Rocket Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Rocket Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Rocket Pharmaceuticals' managers, analysts, and investors.Environmental | Governance | Social |
Rocket Pharmaceuticals Institutional Holders
Institutional Holdings refers to the ownership stake in Rocket Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Rocket Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Rocket Pharmaceuticals' value.| Shares | Geode Capital Management, Llc | 2024-09-30 | 1.6 M | Boxer Capital Llc | 2024-09-30 | 1.5 M | Bank Of America Corp | 2024-06-30 | 1.2 M | Pictet Asset Manangement Sa | 2024-06-30 | 1.2 M | Cowen And Company, Llc | 2024-06-30 | 1.1 M | Novo A/s | 2024-09-30 | 1.1 M | Mpm Oncology Impact Management Lp | 2024-09-30 | 1.1 M | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 952 K | Perceptive Advisors Llc | 2024-09-30 | 931.9 K | Rtw Investments, Llc | 2024-06-30 | 17.7 M | Wellington Management Company Llp | 2024-06-30 | 9.2 M |
Rocket Fundamentals
| Return On Equity | -0.59 | ||||
| Return On Asset | -0.34 | ||||
| Current Valuation | 1.1 B | ||||
| Shares Outstanding | 91.16 M | ||||
| Shares Owned By Insiders | 3.38 % | ||||
| Shares Owned By Institutions | 96.62 % | ||||
| Number Of Shares Shorted | 11.09 M | ||||
| Price To Book | 3.98 X | ||||
| EBITDA | (236.62 M) | ||||
| Net Income | (245.59 M) | ||||
| Cash And Equivalents | 321.37 M | ||||
| Cash Per Share | 4.87 X | ||||
| Total Debt | 25.04 M | ||||
| Debt To Equity | 0.06 % | ||||
| Current Ratio | 13.41 X | ||||
| Book Value Per Share | 3.62 X | ||||
| Cash Flow From Operations | (194.92 M) | ||||
| Short Ratio | 15.00 X | ||||
| Earnings Per Share | (2.73) X | ||||
| Price To Earnings To Growth | 0.03 X | ||||
| Target Price | 46.79 | ||||
| Number Of Employees | 268 | ||||
| Beta | 1.09 | ||||
| Market Capitalization | 1.31 B | ||||
| Total Asset | 566.34 M | ||||
| Retained Earnings | (959.37 M) | ||||
| Working Capital | 329.72 M | ||||
| Net Asset | 566.34 M |
About Rocket Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Rocket Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Rocket Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Rocket Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Rocket Stock Analysis
When running Rocket Pharmaceuticals' price analysis, check to measure Rocket Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rocket Pharmaceuticals is operating at the current time. Most of Rocket Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Rocket Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rocket Pharmaceuticals' price. Additionally, you may evaluate how the addition of Rocket Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.